Iconic Therapeutics has signed an agreement with Novartis that will give Novartis an option on Iconic’s ophthalmology program, according to a press release.
Iconic is evaluating ICON-4, an anti-tissue factor monoclonal antibody, as a potential therapeutic for age-related macular degeneration, the release said, with clinical trials possibly beginning next year.
“Iconic Therapeutics is pursuing an innovative approach to targeting tissue factor, a promising target with early clinical validation and potential applicability in a broad range of diseases, including retinal disease and cancer,”
Uncategorized